Nerlynx was granted marketing authorization by the European Commission for the extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer
in September 2018.
He wrote: "Its routine use in the management of patients with early stage breast cancer
may be unwarranted.
This study is the first large-scale trial to demonstrate the significant antitumor benefit of Zometa[R] and the findings may allow oncologists to further improve the standard of care for premenopausal women with hormone-sensitive early stage breast cancer
Although it is uncertain if these benefits were due to exercise alone, the group experience or a combination of those two factors, it seems likely that a structured exercise program may provide adjunctive benefits for women undergoing treatment for early stage breast cancer
FDA expands the use of trastuzumab (Herceptin) for early stage breast cancer
after primary therapy.
Yesterday, manufacturers Roche went public with the news that the European Commission had granted a licence for the drug to be used across Europe for early stage breast cancer
, after it was recommended by the European Medicines Agency (EMEA).
Yesterday, the European Commission granted a licence for the drug to be used across Europe for early stage breast cancer
after it was recommended by the European Medicines Agency (EMEA).
"At the current time, it is not thought Herceptin will be licensed to treat early stage breast cancer
before summer 2006."
Offering MANAGEMENT several features that facilitate informed, customized healthcare decisions, Better Prepared Decision Support is an interactive Web-based tool intended to help patients evaluate treatment options for three common medical situations: early stage breast cancer
, hip replacement and knee replacement.
Women diagnosed with early stage breast cancer
usually have surgery to remove the tumour followed by radiotherapy of the whole breasts to prevent cancer returning.
* A woman with early stage breast cancer
in Pittsburgh has an eight times greater likelihood of being treated with a radical mastectomy (versus breast-conserving surgery and radiation therapy) than a woman with the same clinical presentation in Sacramento for no known medical reasons.
M2 PHARMA-July 17, 2019-Puma Biotechnology announces receipt by licensing partner of regulatory approval from Health Canada to commercialise NERLYNX for extended adjuvant treatment of HER2-positive early stage breast cancer